Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Fosun Pharma (02196.HK) Subsidiary's New Breast Cancer Neoadjuvant Therapy Approved for Clinical Trial
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
Fosun Pharma (02196.HK) announced that its subsidiary, Shanghai Henlius Biotech and its holding subsidiary Henlius, have received approval from the National Medical Products Administration for HLX319 (pertuzumab-trastuzumab injection (subcutaneous) biosimilar) to conduct a Phase I clinical trial for neoadjuvant therapy in HER2-positive early or locally advanced breast cancer. Henlius plans to conduct relevant clinical research for this drug in China once conditions permit. (ha/da) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
